Brief: Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership
Dec 4 (Reuters) - KELUN-BIOTECH AND CRESCENT BIOPHARMA ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE NOVEL ONCOLOGY THERAPEUTICS CRESCENT BIOPHARMA INC - CR-001 AND SKB105 TO ENTER PHASE 1/2 TRIALS IN Q1 2026 CRESCENT BIOPHARMA INC - KELUN-BIOTECH TO RECEIVE $80 MILLION UPFRONT PAYMENT,ADDITIONAL MILESTONES OF UP TO US$1.25 BILLION FROM CRESCENT CRESCENT BIOPHARMA INC - CO TO RECEIVE $20 MILLION UPFRONT PAYMENT,ADDITIONAL MILESTONES OF UP TO US$30 MILLION FROM KELUN-BIOTECH CRESCENT BIOPHARMA INC - KELUN-BIOTECH ELIGIBLE FOR MILESTONES UP TO $1.25 BILLION Source text: ID:nGNXc0Mj7V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN